Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are closely related progressive and fatal neurodegenerative conditions for which there is no cure. One of the biggest challenges slowing down the pace of ALS and FTD drug discovery research is the lack of consistent, physiologically relevant human cell models that accurately represent disease phenotypes and human pathophysiology in vitro.

We have developed ioDisease Model Cells™ with the aim of solving these challenges. Drug discovery experts can access human iPSC-derived neurons engineered with mutations commonly associated with ALS and FTD. Our TDP-43 and MAPT disease models show disease-related phenotypes of reduced neuronal activity and hyperphosphorylation respectively, when compared to a genetically matched control. ioDisease Model Cells are defined, consistent, and scalable, supporting translational research for the identification of new therapeutics that could halt or reverse the devastating effects of ALS and FTD.

Discover our ioDisease Model Cells for ALS and FTD research and drug discovery below.